Trevi Therapeutics, Inc. TRVI
13.29 USD -0.36 (-2.64%)
Regular-session close
13.29 0.00 0.00%
After hours · Nov 16, 5:56 PM ET
13.15 Day range 13.67
9.82 52-week range 20.22
- YTD
- +6.15%
- 1 year
- +16.89%
News
seekingalpha.com Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
marketbeat.com What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call Trevi Therapeutics NASDAQ: TRVI said it remains on track to report results from its lead chronic cough trials in 2027 and 2028, while preparing a new study in patients with interstitial lung disease…
benzinga.com Trevi Therapeutics Q3 2026 Earnings Call Transcript Trevi Therapeutics (NASDAQ:TRVI) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Trevi Therapeutics Q3 EPS $(0.13), Inline Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 62.5 percent decrease over losses of $(0.08) per share from the…
globenewswire.com Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF…
